Who Are We

The Metro-Minnesota Community Oncology Research Consortium (MMCORC) is a nonprofit research program sponsored by the National Cancer Institute (NCI) and participating hospitals and clinics. Local physician have access to the newest advances in cancer research. The MMCORC links community cancer specialists, primary care physicians and other health care professionals to NCI-approved research studies, called clinical trials.

This program gives people in our community access to:

  • the newest therapies available for cancer treatment.
  • management of treatment side effects and disease symptoms
  • studies directed at cancer prevention
  • molecular-based precision medicine research
  • cancer care delivery research

“Our mission is to provide the opportunity for patients to enroll in a high-quality clinical trial for the treatment or prevention of cancer in their own community while being treated by a local physician. Our dedicated and experienced medical professionals conduct clinical trials with compassion and respect for our participants and offer cutting-edge treatment options. I invite you to learn more about clinical trials, the cancer doctors within your community and the impact of your participation on clinical research in the progress against cancer.”

– Daniel Anderson, MD, Principal Investigator for MMCORC

Our History

MMCORC is an established community program that began in 1979 through a NCI-funded Community Hospital Cancer Program Award. This program was piloted to see if clinical research could successfully be conducted in community hospitals rather than only in major academic hospitals. This proved successful, and in 1983, we received one of the initial Community Clinical Oncology Program (CCOP) grant awards. We have been funded by CCOP grant funding since then. Since we started, we have enrolled more than 15,000 patients into clinical trials.


Currently, the consortium represents 22 hospitals and clinics in Minneapolis-St. Paul, MN and the surrounding suburbs; Stillwater, MN; Willmar, MN; New Ulm, MN; and New Richmond, WI. It also includes more than 160 physician-researchers representing:

  • medical oncology
  • radiation oncology
  • surgical oncology
  • neurosurgery
  • thoracic surgery
  • gynecologic oncology
  • pulmonology

Our portfolio includes more than 100 open clinical trials targeted to specific types of cancer.


Meet the Leadership Team

Daniel Anderson, MD

Principal Investigator

Michele Lacy

Administrative Director

David King, MD

Co-Principal Investigator

Yan Ji, MD

Co-Principal Investigator